Acino: Marketing application for new transparent low dose contraceptive patch in the EU submitted Freitag, 21. September 2012 - 17:49

NEWS RELEASE — PRESSEMITTEILUNG

Marketing application for new transparent low dose contraceptive patch in the EU submitted

Basle, September 21, 2012, 17.30 hrs — Acino’s Partner Bayer HealthCare announced that it has submitted an application for marketing authorization in the European Union for a new transparent low dose contraceptive patch (ethinylestradiol / gestodene). Acino will be manufacturing Bayer HealthCare's patch at its new pharmaceutical manufacturing plant for transdermal therapeutic systems at the company site in Miesbach (Germany).

Find more information on the product at www.bayerpharma.com.

Acino – Delivering Health Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand “Acino Switzerland”,

Acino markets Swiss-quality medicines in up and coming economies, currently in 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Basle, at present has about 850 employees (including staff members from Mepha) and generated annual revenues of EUR 135 million in 2011.

Contact Robert Schmid Media & Investor Relations Phone +41 61 338 61 15 robert.schmid@acino-pharma.com www.acino-pharma.com

Calendar

7.3.2013 Annual Report 2012

7.3.2013 Media and analyst conferences 4.4.2013 General Meeting of Shareholders